• Kevin J Monahan, Nicola Bradshaw, Sunil Dolwani, Bianca Desouza, Malcolm G Dunlop, James E East, Mohammad Ilyas, Asha Kaur, Fiona Lalloo, Andrew Latchford, Matthew D Rutter, Ian Tomlinson, ThomasHuw J WHJWFamily Cancer Clinic, St Mark's Hospital, London, UK.Faculty of Medicine, Imperial College, London, UK., James Hill, and Hereditary CRC guidelines eDelphi consensus group.
• Family Cancer Clinic, St Mark's Hospital, London, UK k.monahan@imperial.ac.uk.
• Gut. 2020 Mar 1; 69 (3): 411-444.

AbstractHeritable factors account for approximately 35% of colorectal cancer (CRC) risk, and almost 30% of the population in the UK have a family history of CRC. The quantification of an individual's lifetime risk of gastrointestinal cancer may incorporate clinical and molecular data, and depends on accurate phenotypic assessment and genetic diagnosis. In turn this may facilitate targeted risk-reducing interventions, including endoscopic surveillance, preventative surgery and chemoprophylaxis, which provide opportunities for cancer prevention. This guideline is an update from the 2010 British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland (BSG/ACPGBI) guidelines for colorectal screening and surveillance in moderate and high-risk groups; however, this guideline is concerned specifically with people who have increased lifetime risk of CRC due to hereditary factors, including those with Lynch syndrome, polyposis or a family history of CRC. On this occasion we invited the UK Cancer Genetics Group (UKCGG), a subgroup within the British Society of Genetic Medicine (BSGM), as a partner to BSG and ACPGBI in the multidisciplinary guideline development process. We also invited external review through the Delphi process by members of the public as well as the steering committees of the European Hereditary Tumour Group (EHTG) and the European Society of Gastrointestinal Endoscopy (ESGE). A systematic review of 10 189 publications was undertaken to develop 67 evidence and expert opinion-based recommendations for the management of hereditary CRC risk. Ten research recommendations are also prioritised to inform clinical management of people at hereditary CRC risk.© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

40 keywords...

hide…